Drug Type Protein drug conjugate |
Synonyms TZT 102, TZT102 |
Target |
Action inhibitors |
Mechanism RAS inhibitors(RAS type GTPase family inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | United States | 01 Sep 2024 | |
| Multiple Myeloma | Preclinical | United States | 01 Sep 2024 | |
| Non-Small Cell Lung Cancer | Preclinical | United States | 01 Sep 2024 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States | 01 Sep 2024 |





